vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and bioAffinity Technologies, Inc. (BIAF). Click either name above to swap in a different company.
bioAffinity Technologies, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.0M, roughly 1.6× AVAX ONE TECHNOLOGY LTD.). bioAffinity Technologies, Inc. runs the higher net margin — -197.0% vs -1633.6%, a 1436.6% gap on every dollar of revenue.
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
AVX vs BIAF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.6M |
| Net Profit | $-16.6M | $-3.1M |
| Gross Margin | — | — |
| Operating Margin | -1522.1% | -196.9% |
| Net Margin | -1633.6% | -197.0% |
| Revenue YoY | — | -27.8% |
| Net Profit YoY | -480.2% | -5.7% |
| EPS (diluted) | $32.17 | $-3.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.6M | ||
| Q3 25 | $525.9K | $1.4M | ||
| Q2 25 | $452.0K | $1.3M | ||
| Q1 25 | $344.4K | $1.9M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $0 | $2.4M | ||
| Q2 24 | $41.3K | $2.4M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | $-16.6M | $-3.1M | ||
| Q3 25 | $-8.4M | $-5.1M | ||
| Q2 25 | $-8.1M | $-4.1M | ||
| Q1 25 | $-145.5K | $-2.7M | ||
| Q4 24 | — | $-3.0M | ||
| Q3 24 | $-5.8M | $-2.0M | ||
| Q2 24 | $-4.2M | $-2.1M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1522.1% | -196.9% | ||
| Q3 25 | -496.6% | -158.6% | ||
| Q2 25 | -328.4% | -198.2% | ||
| Q1 25 | -600.0% | -141.7% | ||
| Q4 24 | — | -133.5% | ||
| Q3 24 | — | -84.0% | ||
| Q2 24 | -2827.7% | -87.1% | ||
| Q1 24 | — | -80.8% |
| Q4 25 | -1633.6% | -197.0% | ||
| Q3 25 | -1588.0% | -349.3% | ||
| Q2 25 | -1783.4% | -319.9% | ||
| Q1 25 | -42.2% | -143.5% | ||
| Q4 24 | — | -134.4% | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | -10243.5% | -88.0% | ||
| Q1 24 | — | -81.5% |
| Q4 25 | $32.17 | $-3.59 | ||
| Q3 25 | $-5.55 | $-4.74 | ||
| Q2 25 | $-27.60 | $-0.17 | ||
| Q1 25 | $-1.17 | $-0.16 | ||
| Q4 24 | — | $-17.27 | ||
| Q3 24 | $-57.19 | $-4.84 | ||
| Q2 24 | $-83.03 | $-0.19 | ||
| Q1 24 | — | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $6.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $7.3M |
| Total Assets | $195.0M | $11.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $6.4M | ||
| Q3 25 | $894.7K | $7.7M | ||
| Q2 25 | $185.3K | $802.8K | ||
| Q1 25 | $1.4M | $444.7K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $756.6K | ||
| Q2 24 | — | $801.3K | ||
| Q1 24 | — | $2.5M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $7.3M | ||
| Q3 25 | $12.2M | $8.9M | ||
| Q2 25 | $4.1M | $-2.1M | ||
| Q1 25 | $6.4M | $1.4M | ||
| Q4 24 | — | $2.6M | ||
| Q3 24 | $6.7M | $3.1M | ||
| Q2 24 | $11.3M | $3.4M | ||
| Q1 24 | — | $5.3M |
| Q4 25 | $195.0M | $11.0M | ||
| Q3 25 | $16.5M | $11.5M | ||
| Q2 25 | $15.2M | $4.8M | ||
| Q1 25 | $16.8M | $5.5M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $10.8M | $6.6M | ||
| Q2 24 | $15.7M | $6.7M | ||
| Q1 24 | — | $8.0M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-2.6M |
| Free Cash FlowOCF − Capex | — | $-2.6M |
| FCF MarginFCF / Revenue | — | -160.7% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-9.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-2.6M | ||
| Q3 25 | $-2.4M | $-2.5M | ||
| Q2 25 | $-884.1K | $-2.6M | ||
| Q1 25 | $-2.2M | $-1.6M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-1.2M | $-1.7M | ||
| Q2 24 | $-919.2K | $-1.5M | ||
| Q1 24 | — | $-2.3M |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-1.7M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | — | -160.7% | ||
| Q3 25 | — | -171.8% | ||
| Q2 25 | — | -209.6% | ||
| Q1 25 | — | -91.3% | ||
| Q4 24 | — | -76.0% | ||
| Q3 24 | — | -73.1% | ||
| Q2 24 | — | -65.1% | ||
| Q1 24 | — | -99.2% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
